Paper · 36928584
Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study.
Shi GM and 22 others. Signal Transduct Target Ther, 2023. Cited by 149 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Download JSON
Cite this record
ConductScience Library. Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study. Papers, record 36928584. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36928584
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study.
- PubMed
- Publication types
- Randomized Controlled Trial, Multicenter Study, Clinical Trial, Phase III, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Bile Duct Neoplasms | Major topic |
| Cholangiocarcinoma | Major topic |
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Humans | |
| B7-H1 Antigen | |
| Bile Ducts, Intrahepatic | |
| Oxaliplatin | |
| Phenylurea Compounds | |
| Quinolines | |
| Antibodies, Monoclonal, Humanized |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials2
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT03951597 | Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT07208526 | A Randomized Trial of Surgical Decision-Making Guided by TDTP-RECIST | Background | ClinicalTrials.gov |
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References30
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28,317,872 | Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody. | Acta Pharmacol Sin | 2017 | https://conductscience.org/library/papers/28317872 | PubMed |
| 2 | 32,984,358 | Anti-PD-1 Immunotherapy and Radiotherapy for Stage IV Intrahepatic Cholangiocarcinoma: A Case Report. | Front Med (Lausanne) | 2020 | https://conductscience.org/library/papers/32984358 | PubMed |
| 3 | 26,373,575 | PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma. | Clin Cancer Res | 2016 | https://conductscience.org/library/papers/26373575 | PubMed |
| 4 | 30,805,896 | Toripalimab: First Global Approval. | Drugs | 2019 | https://conductscience.org/library/papers/30805896 | PubMed |
| 5 | 29,992,241 | Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. | Ann Oncol | 2018 | https://conductscience.org/library/papers/29992241 | PubMed |
| 6 | 38,319,896 | Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. | NEJM Evid | 2022 | https://conductscience.org/library/papers/38319896 | PubMed |
| 7 | 32,233,637 | Treatment of advanced intrahepatic cholangiocarcinoma with sintilimab combined with tegafur-gimeracil-oteracil potassium capsules (S-1): a case report. | Ann Palliat Med | 2020 | https://conductscience.org/library/papers/32233637 | PubMed |
| 8 | 34,341,578 | Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. | Nat Med | 2021 | https://conductscience.org/library/papers/34341578 | PubMed |
| 9 | 31,367,249 | Distinct PD-L1/PD1 Profiles and Clinical Implications in Intrahepatic Cholangiocarcinoma Patients with Different Risk Factors. | Theranostics | 2019 | https://conductscience.org/library/papers/31367249 | PubMed |
| 10 | 31,077,311 | Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials. | J Natl Cancer Inst | 2020 | https://conductscience.org/library/papers/31077311 | PubMed |
1 to 10 of 30
See all 30 referencesCited by123
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 149 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,978,882 | Single-cell and spatial transcriptomics in intrahepatic cholangiocarcinoma: spatial immune ecosystems, metabolic remodeling, and immunotherapeutic implications. | Front Immunol | 2026 | https://conductscience.org/library/papers/42978882 | PubMed |
| 42,947,178 | Targeting circular RNAs to overcome therapeutic resistance in liver cancer: from mechanisms to clinical prospects. | Mol Cancer | 2026 | https://conductscience.org/library/papers/42947178 | PubMed |
| 42,871,963 | The GOLP regimen: pushing the boundaries of conversion therapy in locally advanced biliary tract cancer. | Hepatobiliary Surg Nutr | 2026 | https://conductscience.org/library/papers/42871963 | PubMed |
| 42,871,862 | Neoadjuvant immuno-chemotherapy combined with antiangiogenic therapy for patients with resectable high-risk intrahepatic cholangiocarcinoma and excellent performance status: interim efficacy results from the ZSAB-neoGOLP trial. | Hepatobiliary Surg Nutr | 2026 | https://conductscience.org/library/papers/42871862 | PubMed |
| 42,871,468 | Cryoablation with sintilimab and lenvatinib for intrahepatic cholangiocarcinoma: Does the addition of locoregional therapy augment survival outcomes? | Hepatobiliary Surg Nutr | 2026 | https://conductscience.org/library/papers/42871468 | PubMed |
| 42,856,794 | Targeting TREM2+ and TIMD4+ Macrophages Reprograms the Tumor Microenvironment and Enhances PD-1 Blockade Efficacy in Intrahepatic Cholangiocarcinoma. | Cancer Commun (Lond) | 2026 | https://conductscience.org/library/papers/42856794 | PubMed |
| 42,738,381 | Neoadjuvant Systemic Therapy for Resectable Intrahepatic Cholangiocarcinoma: From Retrospective Studies to Randomized Evidence. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42738381 | PubMed |
| 42,577,326 | Exploratory genomic stratification of benefit from first-line immunotherapy-based combination in advanced biliary tract cancer: a biomarker analysis of a randomized phase 2 trial. | Front Immunol | 2026 | https://conductscience.org/library/papers/42577326 | PubMed |
| 42,511,572 | Advances in Immunotherapy for Intrahepatic Cholangiocarcinoma. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42511572 | PubMed |
| 42,488,106 | Salvage resection for FGFR2 fusion-positive intrahepatic cholangiocarcinoma after pemigatinib therapy: a case report and literature review. | Front Oncol | 2026 | https://conductscience.org/library/papers/42488106 | PubMed |
1 to 10 of 123
See all 123 cited byGenes14
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| BRAF | 673 | PubTator's text mining | https://conductscience.org/library/genes/673 | NCBI Gene |
| CD274 | 29,126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| CTLA4 | 1,493 | PubTator's text mining | https://conductscience.org/library/genes/1493 | NCBI Gene |
| FGFR2 | 2,263 | PubTator's text mining | https://conductscience.org/library/genes/2263 | NCBI Gene |
| GPT | 2,875 | PubTator's text mining | https://conductscience.org/library/genes/2875 | NCBI Gene |
| IDH1 | 3,417 | PubTator's text mining | https://conductscience.org/library/genes/3417 | NCBI Gene |
| KIT | 3,815 | PubTator's text mining | https://conductscience.org/library/genes/3815 | NCBI Gene |
| PDCD1 | 5,133 | PubTator's text mining | https://conductscience.org/library/genes/5133 | NCBI Gene |
| PDGFRA | 5,156 | PubTator's text mining | https://conductscience.org/library/genes/5156 | NCBI Gene |
| RET | 5,979 | PubTator's text mining | https://conductscience.org/library/genes/5979 | NCBI Gene |
1 to 10 of 14
See all 14 genesDrugs4
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| LENVATINIB | CHEMBL1289601 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL1289601 | ChEMBL |
| OXALIPLATIN | CHEMBL414804 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL414804 | ChEMBL |
| TORIPALIMAB | CHEMBL4297843 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL4297843 | ChEMBL |
| GEMCITABINE | CHEMBL888 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL888 | ChEMBL |
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36928584
GET https://conductscience.org/api/papers/v1/36928584/authors?page=2